Table 4. Univariate and multivariate analysis demonstrating the prognostic impact of HPV status on disease-specific survival in OPC.

	Univariate analysis (n = 73)*		Multivariate analysis (n = 73)
Variable	P	HR (95% CI)	P	HR (95% CI)
HPV status (DNA+/mRNA+ vs. Others)	0.029	0.12 (0.01–0.99)	0.061	0.15 (0.02–1.10)
Others include DNA− and DNA+/mRNA−
Age (>50 vs. ≤50 years)	1.000	1.07 (0.20–5.72)
Sex (female vs. male)	0.180	2.51 (0.75–8.39)
T stage (T1–T3 vs. T4)	0.002	0.15 (0.04–0.50)	0.002	0.22 (0.08–0.56)
Nodal stage (N2 or N3 vs. N0 or N1)	0.040	3.49 (1.01–12.03)	0.125	2.46 (0.78–7.76)
Smoking (heavy vs. light or never)	0.059	3.50 (0.90–13.56)
Alcohol drinking (heavy vs. light or never)	0.040	3.49 (1.01–12.03)	0.330	1.78 (0.56–5.70)
Differentiation
Well
Moderate	0.510	1.82 (0.43–7.68)
Poor	0.422	2.58 (0.51–13.01)

HPV, human papillomavirus; HNC, head and neck cancer; HR, hazard ratio;

CI, confidence interval; OPC, oropharyngeal cancer.

*73/74 OPC patients were evaluated since one did not have sufficient tissue for mRNA detection.